VR 942

Drug Profile

VR 942

Alternative Names: Immunomodulatory biologic - respiratory disease - UCB/Vectura; UCB 4144; VR942

Latest Information Update: 17 Dec 2016

Price : $50

At a glance

  • Originator UCB; Vectura
  • Class Antiasthmatics; Biological factors
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Asthma

Most Recent Events

  • 05 Dec 2016 Phase-II clinical trials in Asthma (Inhalation)
  • 23 Nov 2016 Venctura plans a phase II trial
  • 01 Apr 2016 Venctura completed a phase I trial for Asthma (In volunteers) in United Kingdom (NCT02473939)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top